Trazodone's prescribing information specifically notes that men with sickle cell anemia, multiple myeloma, or leukemia may be at higher baseline risk for priapism — a prolonged, medically serious erection unrelated to trazodone specifically, but one that trazodone can trigger. This should be discussed openly with a prescriber weighing treatment options, not treated as a reason to avoid disclosure.
Trazodone with sickle cell disease, multiple myeloma, or leukemia
These conditions are specifically named in trazodone's FDA labeling as raising baseline priapism risk, and should be discussed with a prescriber before starting the medication.
Editorially reviewed
Key points
- Specifically named in FDA labeling as raising baseline priapism risk
- Applies alongside anatomical risk factors like Peyronie's disease
- Open disclosure helps your prescriber weigh the full risk picture
Not medical advice. Always tell your prescriber and pharmacist about every medication, supplement, and substance you use so they can check for interactions specific to your situation.